Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q4 2025 value amounting to $304000.0.

  • Vanda Pharmaceuticals' Depreciation and Depletion rose 1603.05% to $304000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 million, marking a year-over-year increase of 2255.56%. This contributed to the annual value of $1.1 million for FY2025, which is 2255.56% up from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Depreciation and Depletion stood at $304000.0, which was up 1603.05% from $301000.0 recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Depreciation and Depletion high stood at $374000.0 for Q4 2021, and its period low was $200000.0 during Q3 2023.
  • Its 5-year average for Depreciation and Depletion is $277000.0, with a median of $287500.0 in 2022.
  • In the last 5 years, Vanda Pharmaceuticals' Depreciation and Depletion crashed by 3311.04% in 2023 and then surged by 3935.19% in 2025.
  • Vanda Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $374000.0 in 2021, then dropped by 24.06% to $284000.0 in 2022, then decreased by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then increased by 16.03% to $304000.0 in 2025.
  • Its Depreciation and Depletion was $304000.0 in Q4 2025, compared to $301000.0 in Q3 2025 and $267000.0 in Q2 2025.